Skip to main content

Table 3 Most frequent adverse events (≥2% in any treatment arm)

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study

Adverse events

AL dispersible (n = 238)

DP paediatric (n = 231)

Patients with at least one adverse event

156 (65.54)

156 (67.53)

Malaria

61 (25.63)

42 (18.18)

Cough

37 (15.55)

40 (17.32)

Anaemia

10 (4.20)

8 (3.46)

Fever

7 (2.94)

14 (6.06)

Tinea capitis

10 (4.20)

12 (5.19)

Rhinitis

4 (1.68)

13 (5.63)

Gastroenteritis

9 (3.78)

5 (2.16)

Loss of appetite

3 (1.26)

6 (2.59)

Otitis media

7 (2.94)

5 (2.16)

  1. AL: Artemether-lumefantrine; DP: dihydroartemisinin-piperaquine.